These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 9517946)

  • 1. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.
    Li W; Escarpe PA; Eisenberg EJ; Cundy KC; Sweet C; Jakeman KJ; Merson J; Lew W; Williams M; Zhang L; Kim CU; Bischofberger N; Chen MS; Mendel DB
    Antimicrob Agents Chemother; 1998 Mar; 42(3):647-53. PubMed ID: 9517946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
    Mendel DB; Tai CY; Escarpe PA; Li W; Sidwell RW; Huffman JH; Sweet C; Jakeman KJ; Merson J; Lacy SA; Lew W; Williams MA; Zhang L; Chen MS; Bischofberger N; Kim CU
    Antimicrob Agents Chemother; 1998 Mar; 42(3):640-6. PubMed ID: 9517945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104.
    Eisenberg EJ; Bidgood A; Cundy KC
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1949-52. PubMed ID: 9303391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability.
    Schade D; Kotthaus J; Riebling L; Kotthaus J; Müller-Fielitz H; Raasch W; Hoffmann A; Schmidtke M; Clement B
    J Pharm Sci; 2015 Sep; 104(9):3208-19. PubMed ID: 26037932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice.
    Burger RA; Billingsley JL; Huffman JH; Bailey KW; Kim CU; Sidwell RW
    Immunopharmacology; 2000 Apr; 47(1):45-52. PubMed ID: 10708809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.
    Gupta D; Varghese Gupta S; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
    Mol Pharm; 2013 Feb; 10(2):512-22. PubMed ID: 23244438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
    Schade D; Kotthaus J; Riebling L; Kotthaus J; Müller-Fielitz H; Raasch W; Koch O; Seidel N; Schmidtke M; Clement B
    J Med Chem; 2014 Feb; 57(3):759-69. PubMed ID: 24422530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
    Sidwell RW; Huffman JH; Barnard DL; Bailey KW; Wong MH; Morrison A; Syndergaard T; Kim CU
    Antiviral Res; 1998 Feb; 37(2):107-20. PubMed ID: 9588843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.
    He G; Massarella J; Ward P
    Clin Pharmacokinet; 1999 Dec; 37(6):471-84. PubMed ID: 10628898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of oseltamivir phosphonate congeners as anti-influenza agents.
    Cheng TJ; Weinheimer S; Tarbet EB; Jan JT; Cheng YS; Shie JJ; Chen CL; Chen CA; Hsieh WC; Huang PW; Lin WH; Wang SY; Fang JM; Hu OY; Wong CH
    J Med Chem; 2012 Oct; 55(20):8657-70. PubMed ID: 23009169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
    Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
    Snell P; Oo C; Dorr A; Barrett J
    Br J Clin Pharmacol; 2002 Oct; 54(4):372-7. PubMed ID: 12392584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor.
    Lew W; Chen X; Kim CU
    Curr Med Chem; 2000 Jun; 7(6):663-72. PubMed ID: 10702632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of treatment schedule and viral challenge dose on the in vivo influenza virus-inhibitory effects of the orally administered neuraminidase inhibitor GS 4104.
    Sidwell RW; Bailey KW; Bemis PA; Wong MH; Eisenberg EJ; Huffman JH
    Antivir Chem Chemother; 1999 Jul; 10(4):187-93. PubMed ID: 10480737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.
    Tai CY; Escarpe PA; Sidwell RW; Williams MA; Lew W; Wu H; Kim CU; Mendel DB
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3234-41. PubMed ID: 9835519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.
    Oo C; Hill G; Dorr A; Liu B; Boellner S; Ward P
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):411-5. PubMed ID: 12910331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.
    Govorkova EA; Marathe BM; Prevost A; Rehg JE; Webster RG
    Antiviral Res; 2011 Aug; 91(2):81-8. PubMed ID: 21635924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
    Kubo S; Tomozawa T; Kakuta M; Tokumitsu A; Yamashita M
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1256-64. PubMed ID: 20047917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
    Kiso M; Kubo S; Ozawa M; Le QM; Nidom CA; Yamashita M; Kawaoka Y
    PLoS Pathog; 2010 Feb; 6(2):e1000786. PubMed ID: 20195462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamiphosphor monoesters as effective anti-influenza agents.
    Chen CL; Lin TC; Wang SY; Shie JJ; Tsai KC; Cheng YS; Jan JT; Lin CJ; Fang JM; Wong CH
    Eur J Med Chem; 2014 Jun; 81():106-18. PubMed ID: 24836064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.